This study is looking at how Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) affects eye redness, eye pressure (intraocular pressure), and eyelid position in people with glaucoma. Glaucoma is a group of conditions that can damage the optic nerve and cause vision loss. Lumify™ is an FDA-approved eye drop for reducing eye redness. You might be able to join if you are over 18, have primary open-angle glaucoma, and have been using brimonidine 0.1%, 0.15%, or 0.2% eye drops for at least six weeks. The study will measure eye redness at 5, 15, and 30 minutes after using the eye drops. The study is currently recruiting about 60 participants.

Study design

This is an interventional study involving about 60 participants. It compares a single dose of Lumify™ to a single dose of sterile balanced saline solution.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your eye redness will be measured at 5, 15, and 30 minutes after receiving the eye drop.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.